Trump fast tracks psychedelics for mental health treatment

President Donald Trump signed an executive order to facilitate the availability of certain psychedelic drugs for treating mental health conditions, including depression and anxiety. He allocated $50 million in federal funds and instructed the Food and Drug Administration (FDA) to expedite the review of drugs such as psilocybin and ibogaine. During the announcement, Trump humorously asked, "Can I have some, please?" while surrounded by notable figures including Health and Human Services Secretary Robert F. Kennedy Jr. and podcast host Joe Rogan.

Next week, the FDA will issue national priority vouchers to three psychedelics, which FDA Commissioner Mary Makary stated will allow for a rapid review process, potentially completing approvals in just weeks. This marks the first instance of the FDA offering to fast-track any psychedelics. Trump emphasized the urgency of addressing a national mental health crisis, noting that over 14 million American adults suffer from serious mental illness.

The announcement comes as the Department of Veterans Affairs participates in multiple trials involving psychedelics for treating post-traumatic stress disorder (PTSD) among military personnel and veterans. Studies have shown promising results, with a 2025 study indicating that a single dose of LSD could alleviate anxiety and depression for extended periods. Currently, psilocybin and ibogaine are classified as Schedule I drugs, indicating they have no accepted medical use and a high potential for abuse. Trump indicated that his order would expedite the reclassification of these substances, anticipating swift FDA approval.

Power Read: This executive order positions Trump as a proactive leader addressing mental health, potentially increasing his support among veterans and those affected by mental health issues. By aligning with influential figures like Joe Rogan, Trump leverages public interest in psychedelic therapy, which may enhance his political capital. However, the fast-tracking of these drugs exposes the FDA to scrutiny regarding safety and efficacy, especially given the recent rejection of MDMA for PTSD treatment.

What to watch: The FDA's upcoming decisions on the national priority vouchers and the subsequent reviews of psychedelics will be critical in shaping the future of mental health treatment in the U.S.